Healthcare Access & Coverage

Synthesis:

Over the last 24 hours, ongoing shifts in access and coverage models are creating immediate operational tensions for value-based care stakeholders. New evidence from pharmacy and payment models demonstrates that current co-pay structures and alternative funding programs are shifting cost burdens and exacerbating access concerns for chronically ill and high-cost populations, highlighting friction with value-based payment goals and market stability [co-pay models and AFPs]. Additionally, persistent gaps in coverage for high-impact therapies—specifically GLP-1s—are influencing access and outcomes across populations, driving demand for more nuanced, data-driven benefit designs in Medicare and ACO populations [GLP-1 coverage gaps].